Business Context and Reporting Period
This Form 8-K was filed by TenX Keane Acquisition (the "Company") on July 17, 2024. The Company is a Cayman Islands-based special purpose acquisition company (SPAC) and an emerging growth company. It is currently in the process of consummating a business combination with Citius Oncology, Inc., pursuant to a Merger Agreement dated October 23, 2023.
Key Financial Metrics and Obligations
The filing details a specific financial obligation related to extending the deadline for the business combination:
- Extension Payment: $66,667 deposited into the Company's trust account by Citius Pharmaceuticals, Inc. (the Sponsor's designee).
- Debt Instrument: An unsecured promissory note issued by the Company to Citius Pharmaceuticals, Inc. in the principal amount of $66,667.
- Interest Rate: 0% (The note bears no interest).
- Repayment Terms: Repayable in full per the terms of the Merger Agreement.
- Liquidity Impact: The deposit extends the timeline to complete the business combination from July 18, 2024, to August 18, 2024.
The filing does not provide data on revenue, profit, cash flow, or operating margins, as the Company is a pre-combination SPAC.
Material Changes
The primary material change reported is the execution of the fourth extension of the business combination deadline. Three prior extensions were effected on April 26, 2024, May 17, 2024, and June 17, 2024. This filing confirms the fourth extension, moving the deadline to August 18, 2024. The Company has utilized 4 of the 7 allowable one-month extensions permitted under its Charter.
Outlook, Risks, and Management Commentary
Outlook: The Company remains on track to complete its merger with Citius Oncology, Inc., provided the transaction is consummated by the new deadline of August 18, 2024.
Risks and Contingencies: The ability to extend the timeline further is contingent upon the Sponsor or its designee depositing the lesser of $66,667 or $0.03 per public share for each subsequent month. If the business combination is not completed by the final extension date, the Company may be required to liquidate.
Investor Verification Checklist
- Verify the total number of remaining extension periods available (3 of 7 used).
- Confirm the terms of the Merger Agreement regarding the repayment of the $66,667 promissory note.
- Monitor the Company's progress toward closing the merger with Citius Oncology, Inc. before August 18, 2024.
- Review the attached Exhibit 10.4 for the full text of the Promissory Note.